Profound Medical Corp. (NASDAQ:PROF) announced an upsized private placement that will raise up to $6.45 million by issuing 921,428 common shares at $7.00 each. The offering is scheduled to close on or before December 30, 2025, and the proceeds will be used to fund sales and marketing expansion, working‑capital needs, research and development, strategic transactions, and general corporate purposes.
The upsized private placement follows a $40 million equity financing announced on December 19, which comprised a $36 million registered direct offering and a planned $4 million private placement. By increasing the private placement to $6.45 million, Profound is reinforcing its capital structure to support the accelerated commercialization of its flagship TULSA‑PRO platform, an FDA 510(k)‑cleared, MRI‑guided, incision‑free prostate ablation system that has gained CE marking and is expanding into new markets.
The company’s financials underscore the need for additional capital. In the second quarter of 2025, Profound reported revenue of $2.2 million but a net loss of $15.7 million, reflecting ongoing investment in sales, marketing, and product development. With a market capitalization of roughly $230 million, the firm is scaling its commercial operations while maintaining a lean operating model that requires external financing to sustain growth momentum.
Investors typically view such equity issuances with caution due to dilution concerns. While the company’s management emphasizes that the capital will accelerate market penetration of TULSA‑PRO and support strategic acquisitions, the immediate impact on shareholder value is mitigated by the company’s focus on long‑term revenue growth and the potential upside of expanding its product portfolio.
The upsized private placement is part of Profound’s broader strategy to secure the financial resources needed to drive its commercial expansion, strengthen its R&D pipeline, and pursue strategic transactions that could enhance its competitive position in the prostate disease treatment market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.